Steroid hormone agonists and antagonists in the treatment of cancer.
Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City 52242.
R
R
Dreicer
G
G
Wilding
D000726:Androgen Antagonists / Q000378:metabolism / Q000494:pharmacology*; D000728:Androgens / Q000378:metabolism / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D004965:Estrogen Antagonists / Q000378:metabolism / Q000494:pharmacology*; D004967:Estrogens / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000502:physiology; D013629:Tamoxifen / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000378:metabolism
D000726:Androgen Antagonists; D000728:Androgens; D004965:Estrogen Antagonists; D004967:Estrogens; D010982:Platelet-Derived Growth Factor; D011960:Receptors, Estrogen; D016212:Transforming Growth Factor beta; D013629:Tamoxifen; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D005485:Flutamide